Blood-borne amyloid-β dimer correlates with clinical markers of alzheimer's disease

Villemagne, Victor L., Perez, Keyla A., Pike, Kerryn E., Kok, W. Mei, Rowe, Christopher C., White, Anthony R., Bourgeat, Pierrick, Salvado, Olivier, Bedo, Justin, Hutton, Craig A., Faux, Noel G., Masters, Colin L. and Barnham, Kevin J. (2010) Blood-borne amyloid-β dimer correlates with clinical markers of alzheimer's disease. The Journal of Neuroscience, 30 18: 6315-6322. doi:10.1523/JNEUROSCI.5180-09.2010

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ237932_OA.pdf Full text (open access) application/pdf 908.08KB 0
UQ237932_SupplementalData_Figure_OA.pdf Full text (open access) application/pdf 56.76KB 0

Author Villemagne, Victor L.
Perez, Keyla A.
Pike, Kerryn E.
Kok, W. Mei
Rowe, Christopher C.
White, Anthony R.
Bourgeat, Pierrick
Salvado, Olivier
Bedo, Justin
Hutton, Craig A.
Faux, Noel G.
Masters, Colin L.
Barnham, Kevin J.
Title Blood-borne amyloid-β dimer correlates with clinical markers of alzheimer's disease
Journal name The Journal of Neuroscience   Check publisher's open access policy
ISSN 0270-6474
Publication date 2010-05-05
Year available 2010
Sub-type Article (original research)
DOI 10.1523/JNEUROSCI.5180-09.2010
Open Access Status File (Publisher version)
Volume 30
Issue 18
Start page 6315
End page 6322
Total pages 8
Place of publication Washington, DC, U.S.A.
Publisher Society for Neuroscience
Language eng
Abstract Alzheimer's disease (AD) is the most common age-related dementia. Unfortunately due to a lack of validated biomarkers definitive diagnosis relies on the histological demonstration of amyloid-β (Aβ) plaques and tau neurofibrillary tangles. Aβ processing is implicated in AD progression and many therapeutic strategies target various aspects of this biology. While Aβ deposition is the most prominent feature of AD, oligomeric forms of Aβ have been implicated as the toxic species inducing the neuronal dysfunction. Currently there are no methods allowing routine monitoring of levels of such species in living populations. We have used surface enhanced laser desorption ionization time of flight (SELDI-TOF) mass spectrometry incorporating antibody capture to investigate whether the cellular membrane-containing fraction of blood provides a new source of biomarkers. There are significant differences in the mass spectra profiles of AD compared with HC subjects, with significantly higher levels of Aβ monomer and dimer in the blood of AD subjects. Furthermore, levels of these species correlated with clinical markers of AD including brain Aβ burden, cognitive impairment and brain atrophy. These results indicate that fundamental biochemical events relevant to AD can be monitored in blood, and that the species detected may be useful clinical biomarkers for AD. Copyright © 2011 Elsevier B.V. All rights reserved.
Keyword A-beta
Cognitive impairment
Cerebrospinal fluid
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Institute for Molecular Bioscience - Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 53 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 56 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 22 Mar 2011, 20:26:58 EST by Susan Allen on behalf of Institute for Molecular Bioscience